Light therapy before surgery for bile duct cancer
Part of Cancer clinical trials.
This trial tests a light-based treatment called photodynamic therapy (PDT) given before surgery for bile duct cancer. The goal is to see if this approach can help shrink the tumor and make surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with bile duct cancer that has not spread far and may be removable with surgery.
- You have not had radiation or chemotherapy before.
- You are willing to participate and sign a consent form.
- You do not have severe liver disease, bleeding problems, or other major health issues that would make surgery unsafe.
- You are not pregnant or breastfeeding, and you are not allergic to porphyrin drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug (rilvegostomig) to standard chemotherapy before surgery can improve outcomes for patients with early-stage bile duct cancer that can be completely removed. The treatment aims to shrink the tumor and help prevent the cancer from coming back.
This trial tests whether treating hilar bile duct cancer with either radiofrequency ablation (heat) or photodynamic therapy (light-activated medicine) can help patients when surgery isn’t an option. It aims to treat the tumor directly without planned surgery soon.
This trial tests a combination of two chemotherapy drugs and an immunotherapy drug given before surgery for bile duct cancer. The goal is to see if this approach shrinks tumors and lowers the chance of cancer coming back after surgery.
This trial tests a combination of an immunotherapy (adebrelimab), a targeted therapy (apatinib), and two chemotherapy drugs (gemcitabine and cisplatin) given before surgery for biliary tract cancers that are removable but at high risk of coming back. The goal is to see if this approach helps shrink the tumor and improve outcomes after surgery.
This trial tests a combination of chemotherapy, an immunotherapy drug called adebrelimab, and a supportive medication to shrink bile duct or gallbladder tumors before surgery. The goal is to make the tumor easier to remove and improve outcomes.
This trial tests a chemotherapy approach after surgery for bile duct or gallbladder cancers. The goal is to see if giving chemotherapy based on a detailed analysis of your tumor (called 3D-PTA) helps prevent the cancer from coming back.
Hear when a new Cholangiocarcinoma Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.